The lack of talents has become a "roadblock" hindering the high-quality development of the Chinese medicine industry, and the new policy may help break the dilemma

【Pharmaceutical Network Industry News】Traditional Chinese medicine is a treasure of Chinese civilization and has contributed irreplaceable wisdom and strength
to the prosperity of the Chinese nation.
Talents play a supporting role in the development of traditional Chinese medicine, after unremitting efforts in recent years, the construction of traditional Chinese medicine talent team has made great progress, but compared with chemical pharmaceuticals and biological drugs, the lack of high-level talents in traditional Chinese medicine, especially the scientific research personnel of traditional Chinese medicine, has become a "roadblock"
hindering the high-quality development of the traditional Chinese medicine industry.
The lack of Chinese medicine scientific research talents has become a bottleneck in development, and new policies may help break the situation (Image source: Pharma.
com) Data show that in 2021, the average number of R&D personnel in 445 A-share pharmaceutical and biological listed companies will be 18.
5%, and the average number of R&D personnel will be 499
.
In terms of subdivision, the average number of R&D personnel in listed Chinese medicine companies is only 10.
5%, and the average number of R&D personnel is 305, which is significantly lower than the average number of R&D personnel of listed companies in chemical pharmaceuticals and biological products accounting for 19.
3% and 19.
5%, and the average number of R&D personnel is 413 and 319
.
As of October 31, 74 A-share listed Chinese medicine companies have announced their third quarterly reports, and nearly 40% have achieved both revenue
and net profit attributable to the parent.
Among them, the top revenue and net profit rankings include Baiyunshan, Yunnan Baiyao, Buchang Pharmaceutical, China Resources Sanjiu, Tongrentang, Pian Tsaixi, Jichuan Pharmaceutical, etc.
, but from the perspective of the number of R&D personnel of these outstanding Chinese medicine enterprises, their proportion in the total number of companies is not high, basically below 10%, and most of them are mainly
bachelor degrees.
According to the 2021 annual report of Yunnan Baiyao, as of December 31, 2021, the number of R&D personnel of the company was 1,106, accounting for 13.
07%, an increase of 2.
86%
over the previous year's 10.
21%.
Among them, 198 are masters and 522 are
undergraduates.
According to Baiyunshan's 2021 annual report, as of December 31, 2021, the number of its R&D personnel is 520, and the number of R&D personnel accounts for 2.
04% of the company's total number, including 56 doctoral students, 174 master students, 232 undergraduates and 58 junior
colleges 。 According to the 2021 annual report of Buchang Pharmaceutical, as of December 31, 2021, the number of R&D personnel in the company is 518, and the number of R&D personnel accounts for 6.
27% of the company's total number, including 13 doctoral students, 156 master students, 284 undergraduates, 63 junior colleges, and 2 high school and below
.
According to the 2021 annual report of China Resources Sanjiu, as of December 31, 2021, the number of R&D personnel in the company was 455, and the number of R&D personnel accounted for 2.
95%, an increase of 0.
08%
over the previous year.
Among them, 18 are doctors and above, 196 are masters, 195 are undergraduates, 18 are junior colleges, and 13 are
technical secondary school/high school and below.
According to Tongrentang's 2021 annual report, as of December 31, 2021, the number of R&D personnel in the company was 510, and the number of R&D personnel accounted for 2.
68% of the company's total number, including 9 doctoral students, 77 master students, 240 undergraduates, 133 junior colleges, and 54
high school and below 。 According to the 2021 annual report of Pian Tsai, as of December 31, 2021, the company has 199 R&D personnel, and the number of R&D personnel accounts for 7.
70% of the company's total number, including 5 doctoral students, 47 master students, 131 undergraduates and 16 junior
colleges 。 According to Jeju Pharmaceutical's 2021 annual report, as of December 31, 2021, the number of R&D personnel in the company was 683, and the number of R&D personnel accounted for 10.
30% of the company's total number, including 10 doctoral students, 153 master students, 412 undergraduates, 107 junior colleges, and 1 high school and below
.
The analysis believes that the Chinese medicine industry has entered the "fast lane" of development, but the lack of high-level R & D personnel of Chinese medicine, education and age structure are unreasonable, which will lead to insufficient innovation power of
Chinese medicine.
The reason for the shortage of Chinese medicine researchers is mainly due to the fact that Chinese medicine is different from Western medicine, and the way to cultivate Chinese medicine talents is relatively single; Some Chinese medicine companies do not pay enough attention to the importance of talents; Lack of effective cultivation of students' scientific research ability in institutional education; The communication channels of high-level scientific research talents are not smooth; The management of Chinese medicine researchers is related
to factors such as the lack of sound service system.
On October 14, 2022, the State Administration of Traditional Chinese Medicine issued the "14th Five-Year Plan for the Development of Traditional Chinese Medicine Talents" (hereinafter referred to as the "Plan"), which clearly states that it is necessary to strengthen the construction of high-level talents in traditional Chinese medicine, including strengthening the leading talents of traditional Chinese medicine, cultivating top-notch talents of young Chinese medicine, gathering multidisciplinary cross-innovative talents, cultivating high-level talents of integrated traditional Chinese and Western medicine, and implementing the plan of strengthening the talent of the Chinese Academy of Chinese Medical Sciences
。 The industry believes that with the release of favorable policies for Chinese medicine talents, it is of great significance to better solve the problems faced by the development of Chinese medicine talents, and will provide a strong talent guarantee
for the inheritance and innovation of Chinese medicine.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.